Zhang Dongye, Hu Minyi, Chu Timothy, Lin Liangjun, Wang Jingyu, Li Xiaodong, Ke Hua Zhu, Qin Yi-Xian
Dept. of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794-5281, United States.
Dept. of Metabolic Disorders, Amgen, Inc., Thousand Oaks, CA, United States.
Bone. 2016 Jun;87:161-8. doi: 10.1016/j.bone.2016.02.005. Epub 2016 Feb 8.
Osteoporosis is characterized by low bone mass and compromised trabecular architecture, and is commonly occurred in post-menopausal women with estrogen deficiency. In addition, prolonged mechanical unloading, i.e., long term bed rest, can exaggerate the bone loss. Sclerostin is a Wnt signaling antagonist and acts as a negative regulator for bone formation. A sclerostin-neutralizing antibody (Scl-Ab) increased bone mineral density in women with postmenopausal osteoporosis and healthy men. The objective of this study was to characterize the condition of bone loss in ovariectomized (OVX) rats with concurrent mechanical unloading and evaluate the effect of sclerostin antibody treatment in mitigating the prospective severe bone loss conditions in this model. Four-month-old OVX- or sham-operated female SD rats were used in this study. They were subjected to functional disuse induced by hind-limb suspension (HLS) or free ambulance after 2days of arrival. Subcutaneous injections with either vehicle or Scl-Ab at 25mg/kg were made twice per week for 5weeks from the time of HLS. μCT analyses demonstrated a significant decrease in distal metaphyseal trabecular architecture integrity with HLS, OVX and HLS+OVX (bone volume fraction decreased by 29%, 71% and 87% respectively). The significant improvements of various trabecular bone parameters (bone volume fraction increased by 111%, 229% and 297% respectively as compared with placebo group) with the administration of Scl-Ab are associated with stronger mechanical property and increased bone formation by histomorphometry. These results together indicate that Scl-Ab prevented the loss of trabecular bone mass and cortical bone strength in OVX rat model with concurrent mechanical unloading. The data suggested that monoclonal sclerostin-neutralizing antibody represents a promising therapeutic approach for severe osteoporosis induced by estrogen deficiency with concurrent mechanical unloading.
骨质疏松症的特征是骨量低和小梁结构受损,常见于雌激素缺乏的绝经后女性。此外,长期的机械性负荷减少,即长期卧床休息,会加剧骨质流失。硬化蛋白是一种Wnt信号拮抗剂,作为骨形成的负调节因子发挥作用。一种硬化蛋白中和抗体(Scl-Ab)可增加绝经后骨质疏松症女性和健康男性的骨矿物质密度。本研究的目的是表征同时存在机械性负荷减少的去卵巢(OVX)大鼠的骨质流失情况,并评估硬化蛋白抗体治疗对减轻该模型中预期的严重骨质流失情况的效果。本研究使用了4个月大的去卵巢或假手术雌性SD大鼠。它们在到达后2天接受后肢悬吊(HLS)或自由活动诱导的功能废用。从HLS开始,每周两次皮下注射25mg/kg的载体或Scl-Ab,持续5周。μCT分析表明,HLS、OVX和HLS+OVX组的远端干骺端小梁结构完整性显著降低(骨体积分数分别降低29%、71%和87%)。与安慰剂组相比,给予Scl-Ab后各种小梁骨参数有显著改善(骨体积分数分别增加111%、229%和297%),这与更强的力学性能和组织形态计量学显示的骨形成增加有关。这些结果共同表明,Scl-Ab可防止同时存在机械性负荷减少的OVX大鼠模型中小梁骨量和皮质骨强度的损失。数据表明,单克隆硬化蛋白中和抗体是治疗雌激素缺乏并同时存在机械性负荷减少所致严重骨质疏松症的一种有前景的治疗方法。